Compare ARDX & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | CRAI |
|---|---|---|
| Founded | 2007 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2014 | 1998 |
| Metric | ARDX | CRAI |
|---|---|---|
| Price | $5.98 | $189.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 1 |
| Target Price | $10.65 | ★ $239.00 |
| AVG Volume (30 Days) | ★ 2.7M | 77.6K |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | N/A | ★ 34.79 |
| EPS | N/A | ★ 8.34 |
| Revenue | $398,234,000.00 | ★ $731,055,000.00 |
| Revenue This Year | $22.71 | $10.26 |
| Revenue Next Year | $27.81 | $3.48 |
| P/E Ratio | ★ N/A | $22.71 |
| Revenue Growth | ★ 58.12 | 8.69 |
| 52 Week Low | $3.21 | $152.57 |
| 52 Week High | $6.78 | $214.66 |
| Indicator | ARDX | CRAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 61.92 |
| Support Level | $5.49 | $175.15 |
| Resistance Level | $6.02 | $178.74 |
| Average True Range (ATR) | 0.28 | 5.90 |
| MACD | 0.01 | 1.88 |
| Stochastic Oscillator | 75.00 | 94.81 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.